INTRODUCTION
The do's and don'ts when using AIIRAs in daily practice in hypertension: an introduction
PS Sever
Department of Clinical Pharmacology & Therapeutics, St Mary's Medical School, Paddington, London, UK In this issue the authors discuss the topic of angiotensin II receptor antagonists (AIIRAs), with particular focus on candesartan cilexetil, in the context of the most recent management guidelines for hypertension.
Mancia and Grassi highlight the most important new recommendations for treatment: the importance of systolic blood pressure alone, and the lowering of thresholds and target blood pressure particularly in high-risk patients. They also point out that different approaches to drug treatment have been advocated by the Joint National Committee on Prevention, Detection and Evaluation and Treatment of Hypertension and by the WHO-ISH. The former body still recommends initial use of ␤-blockers and diuretics for uncomplicated hypertension, reserving other clases of drugs for those in whom initial therapy is ineffective, poorly tolerated or contra-indicated or where there is co-morbidity warranting preferred selection of a particular class of drug. The WHO-ISH, both in their earlier guidelines and in the most recent guidelines, advocate a more liberal approach based on selection of various treatments depending on patient group. Some evidence in support of the latter view is provided by recent outcome trials, eg Syst-Eur and STOP-II.
These authors also note the comparable efficacy of the newest class of drugs, the AIIRAs, and their position in the new guidelines.
Poulter addresses the important issue of cardiovascular risk assessment and reminds us of the high prevalence of other risk factors for cardiovascular disease (CVD) in the hypertensive population. Different guidelines deal with risk assessment in different ways and this author focuses on the use of the Framingham risk equation to derive risk tables for use in clinical practice. He also highlights the pitfalls in risk assessment and particularly the dominant effect of age when using these tables.
In a subsequent discussion of absolute and rela- tive risk assessment these points are further examined. In the following paper by McInnes and colleagues, case histories are introduced to highlight the issue of absolute versus relative risk assessment in a young hypertensive, a middle-aged diabetic, and a hypertensive with established CVD.
In the last two papers the authors focus on the renin-angiotensin system and its blockade by AIIRAs in general with emphasis on candesartan cilexetil.
Unger, Azizi and Belz discuss the role of angiotensin in the pathogenesis of vascular disease and the sub-classification of the angiotensin receptors. In this context they highlight potentially important differences between AT 1 -receptor blockers and the angiotensin-converting enzyme inhibitors. A review of the pharmacological properties of candesartan cilexetil, with emphasis on its binding characteristics and long duration of action, is completed with reference to a number of important experimental studies in which tissue protective effects of the drug in the prevention of cardiovascular structural pathology is seen to occur through mechanisms that are independent of blood pressure lowering.
The final paper, by Mallion and Baguet, describes the comparative properties derived from in vitro and in vivo studies of a number of AIIRAs. It re-emphasises the particular profile of candesartan cilexetil derived from its high affinity for and slow dissociation from the AT 1 receptor, which accounts for the long-lasting antagonism of vascular responses to angiotensin II and the long duration of action of the drug observed in clinical trials.
The results of on-going outcome trials of AIIRAs, including candesartan cilexetil, are eagerly awaited, and if the promise of these drugs based on experimental data and early clinical studies is borne out in morbidity and mortablity trials then a significant step forward will have been made in cardiovascular therapeutics.
